Skip to main content
. 2014 May 19;14:341. doi: 10.1186/1471-2407-14-341

Figure 3.

Figure 3

Kaplan-Meier estimates of overall survival (A) and progression-free survival (B) for 43 relapsed/primary refractory DLBCL patients treated with rituximab-salvage therapy identified by the saaIPI as intermediate risk (saaIPI =1-2) were further stratified into low or high groups by the ALC/AMC ratio.